Correlation Between Assembly Biosciences and Inhibikase Therapeutics

Can any of the company-specific risk be diversified away by investing in both Assembly Biosciences and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Assembly Biosciences and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Assembly Biosciences and Inhibikase Therapeutics, you can compare the effects of market volatilities on Assembly Biosciences and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Assembly Biosciences with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Assembly Biosciences and Inhibikase Therapeutics.

Diversification Opportunities for Assembly Biosciences and Inhibikase Therapeutics

0.11

Correlation Coefficient

Assembly Biosciences  Inhibikase Therapeutics

Average diversification

The 3 months correlation between Assembly and Inhibikase is 0.11. Overlapping area represents the amount of risk that can be diversified away by holding Assembly Biosciences and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Assembly Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Assembly Biosciences are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Assembly Biosciences i.e., Assembly Biosciences and Inhibikase Therapeutics go up and down completely randomly.

Pair Corralation between Assembly Biosciences and Inhibikase Therapeutics

Given the investment horizon of 90 days Assembly Biosciences is expected to generate 7.03 times less return on investment than Inhibikase Therapeutics. But when comparing it to its historical volatility, Assembly Biosciences is 1.6 times less risky than Inhibikase Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  134.00  in Inhibikase Therapeutics on September 2, 2024 and sell it today you would earn a total of  158.00  from holding Inhibikase Therapeutics or generate 117.91% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Assembly Biosciences  vs.  Inhibikase Therapeutics

Assembly Biosciences

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Assembly Biosciences are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating primary indicators, Assembly Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.

Inhibikase Therapeutics

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Assembly Biosciences and Inhibikase Therapeutics

The main advantage of trading using opposite Assembly Biosciences and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Assembly Biosciences position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.

The idea behind Assembly Biosciences and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.